Abbott secures FDA approval for expanded Eterna MRI labeling

2020 02 25 18 49 3356 Abbott Aacc 2019 400

Abbott has secured approval from the U.S. Food and Drug Administration (FDA) for expanded MRI labeling of it Eterna spinal cord stimulation system.

The approval will allow for a wider selection of MRI conditional lead options for full-body scans of people with chronic pain, the company said.

Eterna includes Abbott's TotalScan MRI technology, which allows for faster scan times; its TriCentrus paddle lead, which offers the widest electrical array for 1.5-tesla scanners; and its Penta five-column paddle lead and Octrode stimulation lead, according to the firm.

Page 1 of 602
Next Page